Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Novel insertion mutation in a non-Jewish Caucasian type 1 Gaucher disease patient

Journal Article · · American Journal of Medical Genetics
;  [1];  [2]
  1. Univ. of Victoria, British Columbia (Canada)
  2. Univ. of Alberta, Edmonton (Canada)

Gaucher disease is the most prevalent lysosomal storage disorder. It is autosomal recessive, resulting in lysosomal glucocerebrosidase deficiency. Three clinical forms of Gaucher disease have been described: type 1 (nonneuronopathic), type 2 (acute neuronopathic), and type 3 (subacute neuronopathic). We performed PCR-thermal cycle sequence analysis of glucocerebrosidase genomic DNA and identified a novel mutation in a non-Jewish type 1 Gaucher disease patient. It is a C insertion in exon 3 at cDNA nucleotide position 122 and genomic nucleotide position 1626. This mutation causes a frameshift and, subsequently, four of the five codons immediately downstream of the insertion were changed while the sixth was converted to a stop codon, resulting in premature termination of protein translation. The 122CC insertion abolishes a Cac81 restriction endonuclease cleavage site, allowing a convenient and reliable method for detection using RFLP analysis of PCR-amplified glucocerebrosidase genomic DNA. The mutation in the other Gaucher allele was found to be an A{r_arrow}G substitution at glucocerebrosidase cDNA nucleotide position 1226 that so far has only been reported among type 1 Gaucher disease patients. Since mutation 122CC causes a frameshift and early termination of protein translation, it most likely results in a meaningless transcript and subsequently no residual glucocerebrosidase enzyme activity. We speculate that mutation 122CC may result in a worse prognosis than mutations associated with partial activity. When present in the homozygous form, it could be a lethal allele similar to what has been postulated for the other known insertion mutation, 84GG. Our patient, who is a compound heterozygote 122CC/1226G, has moderately severe type 1 Gaucher disease. Her clinical response to Ceredase{reg_sign} therapy that began 31 months ago has been favorable, though incomplete. 30 refs., 3 figs., 2 tabs.

OSTI ID:
518295
Journal Information:
American Journal of Medical Genetics, Journal Name: American Journal of Medical Genetics Journal Issue: 2 Vol. 68; ISSN 0148-7299; ISSN AJMGDA
Country of Publication:
United States
Language:
English

Similar Records

DNA analysis of an uncommon missense mutation in a Gaucher disease patient of Jewish-Polish-Russian descent
Journal Article · Wed Jun 01 00:00:00 EDT 1994 · American Journal of Medical Genetics · OSTI ID:67944

Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state
Journal Article · Sat Nov 30 23:00:00 EST 1991 · Proceedings of the National Academy of Sciences of the United States of America; (United States) · OSTI ID:5821087

Genetic heterogeneity in type 1 Gaucher disease: Multiple genotypes in Ashkenazic and non-Ashkenazic individuals
Journal Article · Thu Mar 31 23:00:00 EST 1988 · Proceedings of the National Academy of Sciences of the United States of America; (USA) · OSTI ID:6810199